trending Market Intelligence /marketintelligence/en/news-insights/trending/cnnolr07orhow1pz8r5new2 content esgSubNav
In This List

Profound Medical names 2 directors

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Profound Medical names 2 directors

Profound Medical Corp. shareholders elected two new directors at the company's June 14 annual meeting.

Arthur Rosenthal and Brian Ellacott will serve as independent directors of Ontario-based Profound Medical.

Rosenthal is CEO of gEyeCue Ltd., a development stage medical device company. His previous roles include senior vice president and chief scientific officer of Boston Scientific Corp. and vice president of research and development at C. R. Bard Inc., now a unit of Becton Dickinson and Co.

Ellacott is CEO of Belmont Instrument Corp., a medical device company focused on fluid warming and infusion systems. Previously, he was president and CEO of Laborie Medical Technologies.

Medical device company Profound Medical develops and sells technologies to ablate the prostate gland in patients with prostate cancer.